COYA 202 / Coya Therap - LARVOL DELTA

Coya Therapeutics Secures $10 Million Financing to Advance Clinical and Pre-Clinical Pipeline of Regulatory T Cell Therapeutics (GlobeNewswire) - “Coya Therapeutics, Inc…announced that it has raised approximately $10.3 million from institutional and accredited investors. The financing brings the total funding to date to over $20 million. Proceeds will be used to advance several key therapeutic programs which include: COYA 101, a scalable and expanded autologous Treg cell therapy for amyotrophic lateral sclerosis (ALS) patients, into a well-powered Phase 2b study; COYA 201, an autologous Treg-derived exosome therapeutic for ALS patients into Phase 1 studies; COYA 202, an allogeneic Treg-derived exosome therapeutic for frontal temporal dementia (FTD) into Phase 1 studies…Coya is also preparing a novel biologic program for IND submission for ALS, FTD, and Alzheimer’s disease patients.”

Financing • Alzheimer's Disease • Amyotrophic Lateral Sclerosis • CNS Disorders • Frontotemporal Lobar Degeneration